Hanmi Pharm Co Ltd (128940) - Total Assets
Based on the latest financial reports, Hanmi Pharm Co Ltd (128940) holds total assets worth ₩2.04 Trillion KRW (≈ $1.38 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hanmi Pharm Co Ltd - Total Assets Trend (2010–2024)
This chart illustrates how Hanmi Pharm Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see Hanmi Pharm Co Ltd stock valuation for the company's overall valuation and market capitalisation.
Hanmi Pharm Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Hanmi Pharm Co Ltd's total assets of ₩2.04 Trillion consist of 36.9% current assets and 63.1% non-current assets. Review Hanmi Pharm Co Ltd (128940) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 9.5% |
| Accounts Receivable | ₩238.25 Billion | 11.8% |
| Inventory | ₩300.93 Billion | 14.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩94.14 Billion | 4.7% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how Hanmi Pharm Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Hanmi Pharm Co Ltd stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hanmi Pharm Co Ltd's current assets represent 36.9% of total assets in 2024, an increase from 0.0% in 2010.
- Cash Position: Cash and equivalents constituted 9.5% of total assets in 2024, up from 1.6% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 1.0% in 2010.
- Asset Diversification: The largest asset category is inventory at 14.9% of total assets.
Hanmi Pharm Co Ltd Competitors by Total Assets
Key competitors of Hanmi Pharm Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥29.95 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
ASPEN PHAR.UN.ADR /1 O.N.
F:LDZU
|
Germany | €128.04 Billion |
Hanmi Pharm Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.40 | 1.16 | 1.15 |
| Quick Ratio | 0.86 | 0.69 | 0.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩234.58 Billion | ₩97.99 Billion | ₩80.92 Billion |
Hanmi Pharm Co Ltd - Advanced Valuation Insights
This section examines the relationship between Hanmi Pharm Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.53 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 6.4% |
| Total Assets | ₩2.02 Trillion |
| Market Capitalization | $4.47 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Hanmi Pharm Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Hanmi Pharm Co Ltd's assets grew by 6.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Hanmi Pharm Co Ltd (2010–2024)
The table below shows the annual total assets of Hanmi Pharm Co Ltd from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩2.02 Trillion ≈ $1.37 Billion |
+6.43% |
| 2023-12-31 | ₩1.90 Trillion ≈ $1.29 Billion |
-1.35% |
| 2022-12-31 | ₩1.92 Trillion ≈ $1.30 Billion |
-0.63% |
| 2021-12-31 | ₩1.94 Trillion ≈ $1.31 Billion |
+2.91% |
| 2020-12-31 | ₩1.88 Trillion ≈ $1.28 Billion |
-1.66% |
| 2019-12-31 | ₩1.91 Trillion ≈ $1.30 Billion |
+13.16% |
| 2018-12-31 | ₩1.69 Trillion ≈ $1.15 Billion |
+1.82% |
| 2017-12-31 | ₩1.66 Trillion ≈ $1.13 Billion |
+4.01% |
| 2016-12-31 | ₩1.60 Trillion ≈ $1.08 Billion |
-7.29% |
| 2015-12-31 | ₩1.72 Trillion ≈ $1.17 Billion |
+66.70% |
| 2014-12-31 | ₩1.03 Trillion ≈ $700.28 Million |
+17.31% |
| 2013-12-31 | ₩880.87 Billion ≈ $596.95 Million |
+5.42% |
| 2012-12-31 | ₩835.59 Billion ≈ $566.27 Million |
+6.07% |
| 2011-12-31 | ₩787.75 Billion ≈ $533.85 Million |
+5.35% |
| 2010-12-31 | ₩747.72 Billion ≈ $506.72 Million |
-- |
About Hanmi Pharm Co Ltd
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two activ… Read more